Recently, lifespan and healthspan have been extended in experimental animals using
interventions that are potentially translatable into humans. A great deal of thought and work
is needed beyond the usual steps in drug development to advance these findings into
clinical application. Realistic pre-clinical and clinical trial paradigms need to be devised.
Focusing on subjects with symptoms of age-related diseases or frailty or who are at
imminent risk of developing these problems, measuring effects on short-term, clinically …